Source: International Congress 2018 – Challenges in tuberculosis care
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
N. Agrawal (Mumbai, India), T. Lele (Mumbai, India), P. Vaidya (Mumbai, India), V. Chavhan (Mumbai, India), A. Taegtmeyer (Basel, Switzerland), J. Leuppi (Baselland, Switzerland), P. Chhajed (Mumbai, India). High incidence of new onset joint pain in patients receiving fluoroquinolones as part of anti-tuberculous treatment. 2697

Member's Comments

No comment yet.

Related content which might interest you: Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019 Year: 2019 Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019 Year: 2019 Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Duration of therapy in hospitalised patients with CAP Source: Annual Congress 2007 - An international perspective of the management of hospitalised patients with community-acquired pneumonia Year: 2007 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Six months azithromycin treatment in COPD patients with high risk of further exacerbations Source: International Congress 2017 – Management of COPD Year: 2017 Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006 Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Influence of statin therapy on clinical symptoms, severity and prognosis in patients with community acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006 Incidence and timing of hepatotoxicity due to anti-tuberculous treatment Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 Faster clinical improvement and earlier discharge from hospital in CAP patients under sequential moxifloxacin treatment compared to standard therapy Source: Eur Respir J 2004; 24: Suppl. 48, 188s Year: 2004 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 Macrolide therapy in asthma: limited treatment, long-term improvement Source: Eur Respir J 2009; 33: 1239 Year: 2009 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002